Robbins Umeda LLP has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by members of the Board of Directors (“Board”) of Clarient, Inc. (“Clarient” or the “Company”) (NASDAQ: CLRT) in connection with their efforts to sell Clarient to GE Healthcare, a unit of General Electric Company (NYSE: GE). If the transaction is completed, Clarient shareholders will receive $5.00 in cash for each share of Clarient common stock they hold and $20.00 in cash for each share of Clarient preferred stock they hold. The transaction is expected to close in late 2010 or early 2011.
Robbins Umeda LLP’s investigation concerns whether Clarient’s Board undertook a fair process to obtain fair consideration for all shareholders of Clarient. Specifically, our investigation concerns whether the Company’s Board breached their fiduciary duties to Clarient shareholders by failing to adequately shop the Company before entering into the transaction with GE Healthcare.
If you are a shareholder of Clarient, plan to continue to hold your shares, and would like more information about your rights as a shareholder, please contact attorney Gregory E. Del Gaizo at 800-350-6003 or by e-mail at firstname.lastname@example.org.